keyword
MENU ▼
Read by QxMD icon Read
search

Rivastigmine

keyword
https://www.readbyqxmd.com/read/29318278/effect-of-idalopirdine-as-adjunct-to-cholinesterase-inhibitors-on-change-in-cognition-in-patients-with-alzheimer-disease-three-randomized-clinical-trials
#1
Alireza Atri, Lutz Frölich, Clive Ballard, Pierre N Tariot, José Luis Molinuevo, Neli Boneva, Kristian Windfeld, Lars L Raket, Jeffrey L Cummings
Importance: New therapeutic approaches for Alzheimer disease (AD) are needed. Objective: To assess whether idalopirdine, a selective 5-hydroxytryptamine-6 receptor antagonist, is effective for symptomatic treatment of mild to moderate AD. Design, Setting, and Participants: Three randomized clinical trials that included 2525 patients aged 50 years or older with mild to moderate AD (study 1: n = 933 patients at 119 sites; study 2: n = 858 at 158 sites; and study 3: n = 734 at 126 sites)...
January 9, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29309600/effect-of-cholinergic-treatment-depends-on-cholinergic-integrity-in-early-alzheimer-s-disease
#2
Nils Richter, Nora Beckers, Oezguer A Onur, Markus Dietlein, Marc Tittgemeyer, Lutz Kracht, Bernd Neumaier, Gereon R Fink, Juraj Kukolja
In early Alzheimer's disease, which initially presents with progressive loss of short-term memory, neurodegeneration especially affects cholinergic neurons of the basal forebrain. Pharmacotherapy of Alzheimer's disease therefore often targets the cholinergic system. In contrast, cholinergic pharmacotherapy of mild cognitive impairment is debated since its efficacy to date remains controversial. We here investigated the relationship between cholinergic treatment effects and the integrity of the cholinergic system in mild cognitive impairment due to Alzheimer's disease...
January 4, 2018: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29296621/rivastigmine-decreases-brain-damage-in-hiv-patients-with-mild-cognitive-deficits
#3
Gaetano Perrotta, Guillaume Bonnier, Djalel-Eddine Meskaldji, David Romascano, Ruslan Aydarkhanov, Alessandro Daducci, Samanta Simioni, Matthias Cavassini, Melanie Metral, François Lazeyras, Reto Meuli, Gunnar Krueger, Renaud A Du Pasquier, Cristina Granziera
Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i...
December 2017: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/29248451/features-and-outcomes-of-drugs-for-combination-therapy-as-multi-targets-strategy-to-combat-alzheimer-s-disease
#4
REVIEW
Atish Kumar Sahoo, Jagnehswar Dandapat, Umesh Chandra Dash, Satish Kanhar
ETHNOPHARMACOLOGICAL RELEVANCE: Alzheimer's disease (AD), a deleterious neurodegenerative disorder that impairs memory, cognitive functions and may lead to dementia in late stage of life. The pathogenic cause of AD remains incompletely understood and FDA approved drugs are partial inhibitors rather than curative. Most of drugs are synthetic or natural products as galanthamine is an alkaloid obtained from Galanthus spp. Huperzine A, an alkaloid found in Huperzia spp., gingkolides a diterpenoids from Gingko biloba and many ethnobotanicals like Withania somnifera (L...
December 14, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/29239495/comparisons-between-traditional-medicines-and-pharmacotherapies-for-alzheimer-disease-a-systematic-review-and-meta-analysis-of-cognitive-outcomes
#5
REVIEW
Brian H May, Mei Feng, Anna J Hyde, Helmut Hügel, Su-Yueh Chang, Lin Dong, Xinfeng Guo, Anthony L Zhang, Chuanjian Lu, Charlie C Xue
OBJECTIVES: To evaluate the clinical evidence for traditional medicines (TMs) used in East Asia on measures of cognition in Alzheimer disease, determine the effect sizes at different time points for the TMs and pharmacotherapies, and assess the tolerability of the TMs. METHODS: We searched 12 databases in English, Chinese, and Japanese for eligible randomised controlled trials that compared orally administered TMs with pharmacotherapy and reported cognitive outcomes...
December 14, 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/29213524/delirium-in-the-elderly-a-systematic-review-of-pharmacological-and-non-pharmacological-treatments
#6
Cecília Carboni Tardelli Cerveira, Cláudia Cristina Pupo, Sigrid De Sousa Dos Santos, José Eduardo Mourão Santos
Delirium is a common disorder associated with poor prognosis, especially in the elderly. The impact of different treatment approaches for delirium on morbimortality and long-term welfare is not completely understood. OBJECTIVE: To determine the efficacy of pharmacological and non-pharmacological treatments in elderly patients with delirium. METHODS: This systematic review compared pharmacological and non-pharmacological treatments in patients over 60 years old with delirium...
July 2017: Dementia & Neuropsychologia
https://www.readbyqxmd.com/read/29154400/a-chiral-enantioseparation-generic-strategy-for-anti-alzheimer-and-antifungal-drugs-by-short-end-injection-capillary-electrophoresis-using-an-experimental-design-approach
#7
Ahmed M Abdel-Megied, Rasha S Hanafi, Hassan Y Aboul-Enein
The present study describes a generic strategy using capillary electrophoretic (CE) method for chiral enantioseparation of anti-Alzheimer drugs, namely, donepezil (DON), rivastigmine (RIV), and antifungal drugs, namely, ketoconazole (KET), Itraconazole (ITR), fluconazole (FLU), and sertaconazole (SRT) in which these drugs have different basic and acidic properties. Several modified cyclodextrins (CDs) were applied for enantioseparation of racemates such as highly sulfated α, γ CDs, hydroxyl propyl-β-CD, and Sulfobutyl ether-β-CD...
November 20, 2017: Chirality
https://www.readbyqxmd.com/read/29135926/proline-based-carbamates-as-cholinesterase-inhibitors
#8
Hana Pizova, Marketa Havelkova, Sarka Stepankova, Andrzej Bak, Tereza Kauerova, Violetta Kozik, Michal Oravec, Ales Imramovsky, Peter Kollar, Pavel Bobal, Josef Jampilek
Series of twenty-five benzyl (2S)-2-(arylcarbamoyl)pyrrolidine-1-carboxylates was prepared and completely characterized. All the compounds were tested for their in vitro ability to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), and the selectivity of compounds to individual cholinesterases was determined. Screening of the cytotoxicity of all the compounds was performed using a human monocytic leukaemia THP-1 cell line, and the compounds demonstrated insignificant toxicity. All the compounds showed rather moderate inhibitory effect against AChE; benzyl (2S)-2-[(2-chlorophenyl)carbamoyl]pyrrolidine-1-carboxylate (IC50 = 46...
November 14, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29131306/comparative-effectiveness-and-safety-of-cognitive-enhancers-for-treating-alzheimer-s-disease-systematic-review-and-network-metaanalysis
#9
Andrea C Tricco, Huda M Ashoor, Charlene Soobiah, Patricia Rios, Areti Angeliki Veroniki, Jemila S Hamid, John D Ivory, Paul A Khan, Fatemeh Yazdi, Marco Ghassemi, Erik Blondal, Joanne M Ho, Carmen H Ng, Brenda Hemmelgarn, Sumit R Majumdar, Laure Perrier, Sharon E Straus
BACKGROUND/OBJECTIVES: To examine the comparative effectiveness and safety of cognitive enhancers for Alzheimer's disease (AD). DESIGN: Systematic review and Bayesian network metaanalysis (NMA). SETTING: MEDLINE, EMBASE, Cochrane Library, CINAHL, Ageline (inception-March 2016). PARTICIPANTS: Individuals with AD in randomized controlled trials (RCTs), quasi-RCTs, and nonrandomized studies. INTERVENTION: Any combination of donepezil, rivastigmine, galantamine, or memantine...
September 29, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29119798/a-very-low-dose-of-rivastigmine-induced-pisa-syndrome-in-a-clozapine-treated-patient
#10
Pei-Chun Chao, Juo-Chi Li, Ta-Chuan Yeh, Chin-Bin Yeh
No abstract text is available yet for this article.
November 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29102759/preclinical-profile-of-a-dopamine-d1-potentiator-suggests-therapeutic-utility-in-neurological-and-psychiatric-disorders
#11
Robert F Bruns, Stephen N Mitchell, Keith A Wafford, Alex J Harper, Elaine A Shanks, Guy Carter, Michael J O'Neill, Tracey K Murray, Brian J Eastwood, John M Schaus, James P Beck, Junliang Hao, Jeffrey M Witkin, Xia Li, Eyassu Chernet, Jason S Katner, Hong Wang, John W Ryder, Meghane E Masquelin, Linda K Thompson, Patrick L Love, Deanna L Maren, Julie F Falcone, Michelle M Menezes, Linli Zhang, Charles R Yang, Kjell A Svensson
DETQ, an allosteric potentiator of the dopamine D1 receptor, was tested in therapeutic models that were known to respond to D1 agonists. Because of a species difference in affinity for DETQ, all rodent experiments used transgenic mice expressing the human D1 receptor (hD1 mice). When given alone, DETQ reversed the locomotor depression caused by a low dose of reserpine. DETQ also acted synergistically with L-DOPA to reverse the strong hypokinesia seen with a higher dose of reserpine. These results indicate potential as both monotherapy and adjunct treatment in Parkinson's disease...
January 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29034195/protective-effect-of-hydro-alcoholic-extract-of-salvia-haematodes-wall-root-on-cognitive-functions-in-scopolamine-induced-amnesia-in-rats
#12
Mohammad Shawwal, Badruddeen, Mohammad Khushtar, Md Azizur Rahman
Diminished cholinergic transmission may be responsible for development of amnesia. Hence, the present study was undertaken to investigate the possible protective effect of hydro-alcoholic extract of Salvia haematodes Wall root (HESH) on cognitive functions in scopolamine-induced amnesia in adult Sprague Dawley rats. The rats were divided randomly into five groups each consisting of five rats (n = 5). Rats of the groups I, II, III, IV, and V received orally normal saline (10 ml/kg b. wt.), normal saline (10 ml/kg), standard drug rivastigmine (1...
October 2017: Journal of Traditional and Complementary Medicine
https://www.readbyqxmd.com/read/29032750/longitudinal-neuropsychological-outcome-in-taiwanese-alzheimer-s-disease-patients-treated-with-medication
#13
Yuan-Han Yang, Meng-Ni Wu, Ping-Song Chou, Hui-Chen Su, Sheng-Hsiang Lin, Pi-Shan Sung
Background The longitudinal change of neuropsychological tests (NPTs) in treated Alzheimer's disease (AD) is essential to understand the interplay of a therapeutic response from medication and a disease decline due to degenerative processes. The aim of our study is to investigate the annual cognitive progression as measured by commonly used NPTs in treated AD patients and to assess the potential predictors of disease progression. Methods Participants (N=455) diagnosed with AD and treated with cholinesterase inhibitors (ChEIs) or memantine at memory clinics in three hospitals in southern Taiwan from January 2009 to December 2014 were enrolled in this prospectively registered study...
October 10, 2017: Current Alzheimer Research
https://www.readbyqxmd.com/read/29031070/nature-based-molecules-combined-with-rivastigmine-a-symbiotic-approach-for-the-synthesis-of-new-agents-against-alzheimer-s-disease
#14
Giulia Nesi, Qiuhe Chen, Simona Sestito, Maria Digiacomo, Xiaohong Yang, Shengnan Wang, Rongbiao Pi, Simona Rapposelli
Starting from nature as original source, new potential agents with pleiotropic activities have been synthesized and evaluated as neuroprotective agents. In this work, novel nature-based hybrids, combining antioxidant motifs with rivastigmine, have been designed and synthesized. The biological results revealed that the new compounds inhibit both AChE and BuChE. In particular, lipoic acid hybrids LA1, LA2, LA3 resulted to be the most potent inhibitors of BuChE showing IC50 values ranging from 340 to 378 nM. Analogously, all the compounds were able to inhibit the self β-amyloid1-42 aggregation...
December 1, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28978455/the-present-and-future-of-pharmacotherapy-of-alzheimer-s-disease-a-comprehensive-review
#15
REVIEW
Abhinav Anand, Albert Anosi Patience, Neha Sharma, Navneet Khurana
Alzheimer's disease (AD) is a generalized term used for the loss in memory and other intellectual abilities on levels serious enough to interfere with daily life. It accounts for 60-80% of dementia cases. The characteristic features include aggregation of Amyloid-Beta (Aβ) plaques and Tau Protein Tangles in the nervous tissue of brain. Another important aspect associated with development of AD is the decrease in levels of Acetylcholine (ACh) in brain. The conventional pharmacotherapy of AD employs the use of compounds that inhibit the enzyme acetylcholinesterase (e...
November 15, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28974110/acetylcholinesterase-inhibitors-beneficial-effects-on-comorbidities-in-patients-with-alzheimer-s-disease
#16
Vinod Kaushik, Sarah Toombs Smith, Emmanuel Mikobi, Mukaila A Raji
Elderly patients with Alzheimer's disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions. Polypharmacy increases the risk of drug-drug and drug-disease interactions in these patients who may not be able to communicate early symptoms of adverse drug events. Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). They are also used off-label for other causes of dementia such as Lewy body and vascular dementia...
January 1, 2017: American Journal of Alzheimer's Disease and Other Dementias
https://www.readbyqxmd.com/read/28970454/community-pharmacists-knowledge-regarding-donepezil-averse-effects-and-self-care-recommendations-for-insomnia-for-persons-with-ad
#17
Marketa Marvanova, Paul Jacob Henkel
Alzheimer's disease (AD) impacts millions of individuals worldwide. Since no cure is currently available, acetylcholinesterase inhibitors are symptomatic therapy. This study assessed community pharmacists' knowledge regarding donepezil adverse effects (AEs) and self-care recommendations for insomnia management for persons with AD treated with rivastigmine. This is a cross-sectional, standardized telephone survey of community pharmacists (n = 862) in three study areas: West Virginia, North Dakota/South Dakota, and Southern Oregon/Northern California...
July 28, 2017: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/28966636/heterocyclic-compounds-as-key-structures-for-the-interaction-with-old-and-new-targets-in-alzheimer-s-disease-therapy
#18
REVIEW
Asha Hiremathad, Luca Piemontese
Nowadays, Alzheimer's disease (AD) is widely recognized as a real social problem. In fact, only five drugs are FDA approved for the therapy of this widespread neurodegenerative disease, but with low results so far. Three of them (rivastigmine, donepezil and galantamine) are acetylcholinesterase inhibitors, memantine is a N-methyl-D-aspartate receptor antagonist, whereas the fifth formulation is a combination of donepezil with memantine. The prevention and treatment of AD is the new challenge for pharmaceutical industry, as well as for public institutions, physicians, patients, and their families...
August 2017: Neural Regeneration Research
https://www.readbyqxmd.com/read/28923321/nose-to-brain-delivery-of-rivastigmine-by-in-situ-gelling-cationic-nanostructured-lipid-carriers-enhanced-brain-distribution-and-pharmacodynamics
#19
Preeti Wavikar, Rohan Pai, Pradeep Vavia
Present investigation explores the potential of nanostructured lipid carriers (NLCs) for nose to brain delivery of rivastigmine (RV), which is further enhanced by incorporating into an in situ gelling system, increasing retention in nasal cavity. NLCs having particle size of 123.2 ± 2.3 nm, entrapment efficiency of 68.3 ± 3.4%, and zeta potential of 32 ± 1.2 mV was fabricated by a scalable method. Pharmacokinetics showed sustained release of intranasal (IN) and intravenous (IV) NLCs compared with RV solution by same route, with significantly higher AUC and Thalf...
September 15, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28901528/beyond-symptomatic-effects-donepezil-s-potential-for-neuroprotection-and-disease-modification-in-alzheimer-s-disease
#20
REVIEW
Seung Hyun Kim, Nagaendran Kandiah, Jung-Lung Hsu, Chuthamanee Suthisisang, Chesda Udommongkol, Amitabh Dash
Alzheimer's disease (AD) is associated with neurodegenerative changes resulting clinically in progressive cognitive and functional deficits. The only therapies are the cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine and the N-methyl-D-aspartate-receptor antagonist memantine. Donepezil acts primarily on the cholinergic system as symptomatic treatment, but it also has potential for disease modification and may reduce the rate of progression of AD. This review explores the potential for a disease modifying effect of donepezil...
September 13, 2017: British Journal of Pharmacology
keyword
keyword
17106
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"